We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany.
- Authors
Kulp, Werner; Graf von de Schulenburg, J.-M.; Greiner, Wolfgang
- Abstract
We investigated the cost-effectiveness of escitalopram (10 mg daily dose) vs. venlafaxine XR (75 mg daily dose) in a German outpatient setting for the treatment of unipolar depression (MADRS score 20–34) over a period of 70 days. To assess the cost effectiveness of the two substances we combined data from physician’s surveys and clinical response data; cost-effectiveness was calculated using a Markov model. In a second step we considered the therapeutic decisions of the attending physicians. Cost-effectiveness was indicated as costs per successfully treated patient. Escitalopram demonstrated a more favorable cost-effectiveness ratio than venlafaxine XR. The analysis of treatment patterns showed that attending physicians intervene fairly early if the chosen therapy is ineffective. Additional costs for the use of venlafaxine XR over those of escitalopram were estimated from €7,446 to €9.836 per successfully treated per patient. Hence escitalopram may be a cost-effective alternative to venlafaxine XR in outpatient care setting in Germany.
- Subjects
GERMANY; ANTIDEPRESSANTS; MENTAL depression; VENLAFAXINE; NEUROTRANSMITTER uptake inhibitors; DEPRESSED persons
- Publication
European Journal of Health Economics, 2005, Vol 6, Issue 4, p317
- ISSN
1618-7598
- Publication type
Article
- DOI
10.1007/s10198-005-0306-1